Does FATE pay dividends?

Fate Therapeutics Inc (FATE) does not currently pay a regular dividend.

What is FATE's market cap?

Fate Therapeutics Inc (FATE) has a market capitalization of $286.37M with a current stock price of $2.39.

Fate Therapeutics Inc (FATE)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$2.39

-0.04 (-1.65%)

Market Cap: $286.37M

Last updated: Sep 01, 2026 at 5:00 PM ET

Earnings

Performance (10Y)

Beat Rate

55%(22/40)

Avg Surprise

-1.71%

Streak

6 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.26

Range$-0.28 - $-0.21

8 analysts

EPS RevisionsNo revisions (7d)

30d

EPS Estimate Drift

90d ago$-0.26-2.9%

60d ago$-0.26-2.8%

30d ago$-0.26-2.8%

7d ago$-0.26-2.8%

Current$-0.26

Revenue Consensus

$1M

Range$0 - $3M

12 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.23

Range$-0.32 - $-0.09

8 analysts

Revenue Consensus

$2M

Range$-640340 - $4M

11 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.23	$-0.32 - $-0.09	-	-	8	-	-
Sep 30, 2026Sep 26EST	-	$-0.26	$-0.28 - $-0.21	-	-	8	1 0 30d	-
Jun 30, 2026Jun 26 Reported Aug 11, 2026Reported Aug 11	$-0.25	$-0.28	$-0.28 - $-0.22	+10.71%	Beat	9	1 0 30d	+13.8%
Mar 31, 2026Mar 26 Reported May 13, 2026Reported May 13	$-0.26	$-0.28	$-0.30 - $-0.25	+7.14%	Beat	8	1 0 30d	+18.8%
Dec 31, 2025Dec 25 Reported Feb 26, 2026Reported Feb 26	$-0.27	$-0.27	$-0.29 - $-0.25	+0.00%	Beat	8	3 2 30d	+38.6%
Sep 30, 2025Sep 25 Reported Nov 13, 2025Reported Nov 13	$-0.27	$-0.28	$-0.37 - $-0.23	+3.57%	Beat	9	0 1 30d	+32.5%
Jun 30, 2025Jun 25 Reported Aug 12, 2025Reported Aug 12	$-0.29	$-0.34	$-0.44 - $-0.27	+14.71%	Beat	11	4 1 30d	+12.1%
Mar 31, 2025Mar 25 Reported May 13, 2025Reported May 13	$-0.32	$-0.38	$-0.43 - $-0.28	+15.79%	Beat	7	5 0 30d	+31.9%
Dec 31, 2024Dec 24 Reported Mar 5, 2025Reported Mar 5	$-0.44	$-0.42	$-0.49 - $-0.35	-3.82%	Miss	13	2 7 30d	+2.2%
Sep 30, 2024Sep 24 Reported Nov 12, 2024Reported Nov 12	$-0.40	$-0.41	$-0.66 - $-0.37	+2.44%	Beat	18	No revisions (30d)	+13.0%
Jun 30, 2024Jun 24 Reported Aug 13, 2024Reported Aug 13	$-0.33	$-0.45	$-0.64 - $-0.40	+26.67%	Beat	18	No revisions (30d)	+38.9%
Mar 31, 2024Mar 24 Reported May 9, 2024Reported May 9	$-0.47	$-0.45	$-0.67 - $-0.42	-4.44%	Miss	18	1 0 30d	-147.4%
Dec 31, 2023Dec 23 Reported Feb 26, 2024Reported Feb 26	$-0.45	$-0.52	$-0.71 - $-0.32	+13.46%	Beat	21	No revisions (30d)	+22.4%
Sep 30, 2023Sep 23 Reported Nov 8, 2023Reported Nov 8	$-0.46	$-0.56	$-0.76 - $-0.37	+17.86%	Beat	21	1 0 30d	+46.5%
Jun 30, 2023Jun 23 Reported Aug 8, 2023Reported Aug 8	$-0.54	$-0.58	$-0.78 - $-0.34	+6.90%	Beat	21	No revisions (30d)	+30.8%
Mar 31, 2023Mar 23 Reported May 3, 2023Reported May 3	$-0.19	N/A	-	+69.35%	Beat	21	No revisions (30d)	+72.1%
Dec 31, 2022Dec 22 Reported Feb 28, 2023Reported Feb 28	$-0.58	$-0.86	$-1.12 - $-0.56	+32.56%	Beat	24	1 0 30d	+19.4%
Sep 30, 2022Sep 22 Reported Nov 3, 2022Reported Nov 3	$-0.86	$-0.87	$-1.06 - $-0.77	+1.15%	Beat	22	No revisions (30d)	-91.1%
Jun 30, 2022Jun 22 Reported Aug 3, 2022Reported Aug 3	$-0.78	$-0.81	$-1.00 - $-0.65	+3.70%	Beat	22	No revisions (30d)	-34.5%
Mar 31, 2022Mar 22 Reported May 4, 2022Reported May 4	$-0.68	$-0.74	$-0.90 - $-0.63	+8.11%	Beat	19	0 1 30d	-54.5%
Dec 31, 2021Dec 21 Reported Feb 28, 2022Reported Feb 28	$-0.72	$-0.67	$-0.94 - $-0.41	-7.46%	Miss	19	1 0 30d	-18.0%
Sep 30, 2021Sep 21 Reported Nov 4, 2021Reported Nov 4	$-0.45	$-0.55	$-0.74 - $-0.41	+18.18%	Beat	16	3 0 30d	+33.8%
Jun 30, 2021Jun 21 Reported Aug 4, 2021Reported Aug 4	$-0.58	$-0.52	$-0.60 - $-0.41	-11.54%	Miss	14	No revisions (30d)	-65.7%
Mar 31, 2021Mar 21 Reported May 5, 2021Reported May 5	$-0.44	$-0.43	$-0.52 - $-0.31	-2.33%	Miss	15	1 0 30d	+0.0%
Dec 31, 2020Dec 20 Reported Feb 24, 2021Reported Feb 24	$-0.61	$-0.39	$-0.43 - $-0.34	-56.41%	Miss	16	1 0 30d	-64.9%
Sep 30, 2020Sep 20 Reported Nov 5, 2020Reported Nov 5	$-0.68	$-0.36	$-0.44 - $-0.31	-88.89%	Miss	15	No revisions (30d)	-70.0%
Jun 30, 2020Jun 20 Reported Aug 5, 2020Reported Aug 5	$-0.35	$-0.29	$-0.47 - $0.22	-20.69%	Miss	16	No revisions (30d)	+2.8%
Mar 31, 2020Mar 20 Reported May 11, 2020Reported May 11	$-0.44	$-0.39	$-0.45 - $-0.29	-12.82%	Miss	16	1 0 30d	-46.7%
Dec 31, 2019Dec 19 Reported Mar 2, 2020Reported Mar 2	$-0.37	$-0.39	$-0.48 - $-0.28	+5.13%	Beat	15	No revisions (30d)	-48.0%
Sep 30, 2019Sep 19 Reported Nov 5, 2019Reported Nov 5	$-0.40	$-0.37	$-0.41 - $-0.30	-8.11%	Miss	14	1 0 30d	-29.0%
Jun 30, 2019Jun 19 Reported Aug 6, 2019Reported Aug 6	$-0.36	$-0.31	$-0.39 - $-0.18	-16.13%	Miss	12	No revisions (30d)	+2.7%
Mar 31, 2019Mar 19 Reported May 7, 2019Reported May 7	$-0.30	$-0.23	$-0.27 - $-0.17	-30.43%	Miss	8	No revisions (30d)	-11.1%
Dec 31, 2018Dec 18 Reported Mar 5, 2019Reported Mar 5	$-0.25	$-0.24	$-0.34 - $-0.10	-4.17%	Miss	8	1 0 30d	+13.8%
Sep 30, 2018Sep 18 Reported Nov 1, 2018Reported Nov 1	$-0.31	$-0.28	$-0.36 - $-0.10	-10.71%	Miss	7	No revisions (30d)	-24.0%
Jun 30, 2018Jun 18 Reported Aug 6, 2018Reported Aug 6	$-0.37	$-0.32	$-0.38 - $-0.18	-15.63%	Miss	7	No revisions (30d)	-60.9%
Mar 31, 2018Mar 18 Reported May 10, 2018Reported May 10	$-0.27	$-0.22	$-0.25 - $-0.17	-22.73%	Miss	6	No revisions (30d)	-12.5%
Dec 31, 2017Dec 17 Reported Mar 5, 2018Reported Mar 5	$-0.29	$-0.24	$-0.27 - $-0.21	-20.83%	Miss	7	1 0 30d	-38.1%
Sep 30, 2017Sep 17 Reported Nov 1, 2017Reported Nov 1	$-0.25	$-0.25	$-0.26 - $-0.24	+0.00%	Beat	5	No revisions (30d)	+7.4%
Jun 30, 2017Jun 17 Reported Aug 14, 2017Reported Aug 14	$-0.23	$-0.23	$-0.27 - $-0.20	+0.00%	Beat	5	No revisions (30d)	-
Mar 31, 2017Mar 17 Reported May 15, 2017Reported May 15	$-0.24	$-0.20	$-0.22 - $-0.19	-20.00%	Miss	5	No revisions (30d)	-
Dec 31, 2016Dec 16 Reported Mar 16, 2017Reported Mar 16	$-0.21	$-0.29	-	+27.59%	Beat	-	-	-
Sep 30, 2016Sep 16 Reported Nov 7, 2016Reported Nov 7	$-0.27	$-0.28	-	+3.57%	Beat	-	-	-

Key Metrics

Valuation
P/E Ratio	-2.28	EV/EBITDA	-2.59x
Price/FCF	-2.72x	FCF Yield	-36.72%
Profitability
Profit Margin	0.00%	Operating Margin	-1495.00%
ROE	-60.80%	ROIC	N/A
Financial Health
Debt/Equity	N/A	Interest Coverage	N/A
Current Ratio	4.85x	Quick Ratio	4.85x
Trading Statistics
Beta	2.55	Avg Volume	2.02M
52-Week High	$3.23	52-Week Low	$0.93

Technical Indicators Dashboard

Moving Averages

SMA 10$2.49

SMA 20$2.56

SMA 50$2.60

SMA 200$1.70

EMA 10$2.49

EMA 20$2.53

EMA 50$2.48

EMA 200$1.91

MACD

Line: -0.03Signal: -0.02Hist: -0.02

ADX

ADX: 13.5+DI: 18.2-DI: 27.3

Aroon & PSAR

Aroon Up36.0

Aroon Down80.0

PSAR$2.68

Bollinger Bands

Upper Band$2.82

Lower Band$2.31

%B Position1962%(Upper)

Band Width0.15

RSI (14-Day)

Neutral

43.6

Momentum Oscillators

Stoch %K36.0

Stoch %D43.8

Williams %R-74.2

ROC (10d)-8.8%

Momentum-0.23

CCI (20d)-130.8

MFI (14d)36.7

Volatility Measures

ATR (14d)$0.17(7.1%)

StdDev (20d)0.13

Hist Vol73.9%(High)

Volume Flow

VWAP$2.40

OBV64.6M

AD Line7.0M

CMF (20d)-0.103

Volume Metrics

Avg Vol (20d)2.1M

Vol Ratio0.3x(Low)

VWMA (20d)$2.59

Pivot Points

R3$2.62

R2$2.58

R1$2.50

Pivot Point$2.46

S1$2.38

S2$2.34

S3$2.26

Advanced Oscillators

TSI-5.15

Ultimate Osc45.4

KST-55.42

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$2.08M	$1.30M	$1.37M	$1.74M	$1.91M	$1.63M	$1.86M	$3.07M	$6.77M	$1.93M	$1.68M	$1.94M
Cost of Revenue	$0	$0	$3.06M	$0	$0	$0	$17.14M	$0	$0	$0	$4.88M	$0
Gross Profit	$2.08M	$1.30M	$1.37M	$1.74M	$1.91M	$1.63M	$1.86M	$3.07M	$6.77M	$1.93M	$1.68M	$1.94M

Operating Expenses	$33.22M	$34.30M	$36.09M	$36.48M	$38.88M	$42.91M	$63.61M	$55.45M	$51.85M	$52.99M	$49.75M	$53.22M
R&D	$24.39M	$24.70M	$25.43M	$25.84M	$27.43M	$29.14M	$33.61M	$34.65M	$34.60M	$32.14M	$31.82M	$34.27M
SG&A	$8.83M	$9.60M	$10.66M	$10.64M	$11.45M	$13.77M	$15.26M	$20.80M	$17.25M	$20.86M	$17.93M	$18.95M
Operating Income	$-31,134,000	$-33,000,000	$-34,721,000	$-34,735,000	$-36,968,000	$-41,280,000	$-61,748,000	$-52,377,000	$-45,083,000	$-51,068,000	$-48,075,000	$-51,279,000

Interest Income	$1.55M	$1.87M	$2.22M	$2.58M	$2.92M	$3.34M	$3.87M	$4.44M	$4.83M	$4.15M	$4.41M	$4.70M
Interest Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Income Before Tax	$-30,159,000	$-31,213,000	$-32,374,000	$-32,250,000	$-34,070,000	$-37,621,000	$-52,153,000	$-47,678,000	$-38,427,000	$-48,004,000	$-44,122,000	$-45,170,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$-30,159,000	$-31,213,000	$-32,374,000	$-32,250,000	$-34,070,000	$-37,621,000	$-52,153,000	$-47,678,000	$-38,427,000	$-48,004,000	$-44,122,000	$-45,170,000

EBITDA	$-29,698,000	$-30,934,000	$-32,412,000	$-32,408,000	$-34,560,000	$-38,692,000	$-52,744,000	$-49,705,000	$-41,256,000	$-49,963,000	$-46,557,000	$-48,384,000
EBIT	$-31,714,000	$-33,080,000	$-34,594,000	$-34,825,000	$-36,991,000	$-40,957,000	$-56,027,000	$-52,116,000	$-43,254,000	$-52,153,000	$-48,536,000	$-49,867,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about FATE

News

574,995 Shares in Fate Therapeutics, Inc. $FATE Acquired by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. has acquired 574,995 shares of Fate Therapeutics, Inc. (NASDAQ:FATE) during the second quarter, valued at approximately $1.55 million, giving them a 0.49% stake in the company. Institutional investors collectively own 97.54% of Fate Therapeutics. Analyst sentiment for FATE is mixed, with a consensus "Hold" rating and an average target price of $5.90, despite the stock trading down 4.3% recently.

MarketBeat•Aug 30, 2026 7:07 PM8/30/26•

Neutral

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of "Hold" by Brokerages

Fate Therapeutics, Inc. (NASDAQ:FATE) has received a consensus "Hold" rating from eight brokerages, with an average 12-month price target of $5.90. The biopharmaceutical company, which focuses on iPSC-derived cellular immunotherapies, reported quarterly revenue of $2.08 million and an adjusted loss of $0.25 per share, matching analyst expectations. Institutional investors hold a significant 97.54% stake in the company, with recent activity from BlackRock and Johnson & Johnson.

MarketBeat•Aug 20, 2026 7:12 AM8/20/26•

Neutral

Dimensional Fund Advisors LP Lowers Stock Holdings in Fate Therapeutics, Inc. $FATE

Dimensional Fund Advisors LP significantly reduced its stake in Fate Therapeutics, Inc. by 44.0% in the first quarter, selling 693,688 shares and retaining 883,790 shares valued at approximately $1.06 million. Despite this, institutional investors and hedge funds still collectively own 97.54% of the company. Fate Therapeutics reported an EPS of -$0.25, meeting analyst expectations, with revenue exceeding forecasts, though the company remains unprofitable and analysts project a full-year EPS loss of $1.04.

MarketBeat•Aug 15, 2026 7:41 AM8/15/26•

Somewhat-Bearish

Fate Therapeutics (FATE) Stock Drifts Higher Despite Persistent Cash Burn

Fate Therapeutics (FATE) stock saw a modest increase despite reporting significant losses in Q2 2026, with a net loss of US$30 million. While the company's revenue slightly increased year-over-year and losses narrowed, funding risk remains due to its substantial cash burn. Bullish sentiment is supported by positive early clinical data for FT819, but skeptics point to the ongoing losses and recent stock price declines.

Simply Wall Street•Aug 14, 2026 11:41 PM8/14/26•

Neutral

Fate Therapeutics Doses First Patient in Phase 2 RECLAIM-LN Trial of FT819 for Lupus Nephritis

Fate Therapeutics has dosed the first patient in its Phase 2 RECLAIM-LN trial for FT819, an off-the-shelf CAR T-cell therapy aimed at treating refractory moderate-to-severe systemic lupus erythematosus with lupus nephritis. The trial, which plans to enroll approximately 53 patients, will evaluate FT819's efficacy and safety, with complete renal response at Week 26 as the primary endpoint. This study benefits from FDA's RMAT designation and participation in the CMC Development and Readiness Pilot program, indicating a potential for an accelerated regulatory path.

Quiver Quantitative•Aug 14, 2026 10:10 PM8/14/26•

Somewhat-Bullish

Frequently Asked Questions About FATE

Does FATE pay dividends?: Fate Therapeutics Inc (FATE) does not currently pay a regular dividend.
What is FATE's market cap?: Fate Therapeutics Inc (FATE) has a market capitalization of $286.37M with a current stock price of $2.39.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In